DAEWOONG PHARMA
Founded in 2002 via spin-off from Daewoong Co. and KOSPI-listed the same year, Daewoong Pharma is known for Nabota, Fexuclue, and Enblo.
As of 2026-10-11, DAEWOONG PHARMA has 2 Korean MFDS device approvals, 380 Korean MFDS drug approvals, 1 US FDA clearance/approval, 136 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureDaewoong Pharmaceutical was established in October 2002 via spin-off from Daewoong Co., Ltd. and listed on KOSPI in November 2002 as a pharmaceutical manufacturer and distributor. Key products include the new drugs Fexuclue (Korea's 34th new drug) and Enblo (Korea's 36th new drug, an SGLT-2 inhibitor), Woorusa, and the botulinum toxin Nabota, plus digital healthcare products such as the FreeStyle Libre glucose monitor, MobiCare wearable ECG, CartBP blood pressure ring, and the Wiski AI diagnostic-assist solution. In 2025 on a separate basis, the company posted revenue of KRW 1,391.0 billion and operating profit of KRW 203.6 billion, with Nabota contributing KRW 228.9 billion in sales, about 16.5% of revenue, and roughly 84% export share.
Products & technology
- NabotaBotulinum toxin (aesthetic toxin)
- FexuclueKorea's 34th locally developed new drug
- EnbloKorea's 36th new drug, SGLT-2 inhibitor
- Woorusa
- thynC™AI-based smart bedside monitoring system
- FreeStyle LibreContinuous glucose monitor
- MobiCareWearable ECG device
- CartBPRing-type continuous blood pressure monitor
- WiskiAI diagnostic-assist solution for blindness-causing diseases
Regulatory approvals
data.go.kr · openFDA380 Korean MFDS drug approvals · 1970–2026 / 2 Korean MFDS device approvals · 2016–2024 / 1 US FDA drug approvals · 2015
- MFDS drugMagon OneShot2026-09-21Drug · OTC · Notification202602831
- MFDS drugCONPRO TAB. 1.25MG(Bisoprolol Fumarate)2026-09-21Drug · Prescription · Approval202602852
- MFDS drugCONPRO TAB. 5MG(Bisoprolol Fumarate)2026-09-17Drug · Prescription · Approval202602815
- MFDS drugImpactamin Ora Tab.2026-09-10Drug · OTC · Notification202602710
- MFDS drugRuxovi tablet 20mg(Ruxolitinib Hemifumarate)2026-07-24Drug · Prescription · Approval202602140
- MFDS drugRuxovi tablet 10mg(Ruxolitinib Hemifumarate)2026-07-24Drug · Prescription · Approval202602141
- MFDS drugRuxovi tablet 5mg(Ruxolitinib Hemifumarate)2026-07-24Drug · Prescription · Approval202602142
- MFDS drugRuxovi tablet 15mg(Ruxolitinib Hemifumarate)2026-07-24Drug · Prescription · Approval202602143
- MFDS drugPancreno Tab. 250002026-06-22Drug · OTC · Approval202601752
- MFDS drugBaricynaps 4mg (Baricitinib)2026-06-22Drug · Prescription · Approval202601753
- MFDS drugTerbicleone Tab. 250mg2026-05-12Drug · Prescription · Approval202601375
- MFDS drugNoseBalance Nasal Spray2026-04-09Drug · OTC · Notification202601009
Show 68 more
- MFDS drugEasyWhiQCream(Hydroquinone)2026-02-25Drug · OTC · Notification202600562
- MFDS drugBAROEZET TAB. 1/10MG2026-01-29Drug · Prescription · Approval202600266
- MFDS drugBrivatop tab.10mg(Brivaracetam)2025-09-11Drug · Prescription · Approval202502405
- MFDS drugBrivatop tab.25mg(Brivaracetam)2025-09-11Drug · Prescription · Approval202502406
- MFDS drugBrivatop tab.50mg(Brivaracetam)2025-09-11Drug · Prescription · Approval202502407
- MFDS drugBrivatop tab.100mg(Brivaracetam)2025-09-11Drug · Prescription · Approval202502408
- MFDS drugEasyScaroff gel2025-07-23Drug · OTC · Notification202501870
- MFDS drugEasyToningCream(Hydroquinone)2025-07-21Drug · OTC · Notification202501833
- MFDS drugC-Cold Premium Tab.2025-07-10Drug · OTC · Notification202501737
- MFDS drugDaewoong Miglitol Tab.2025-07-07Drug · Prescription · Approval202501687
- MFDS drugXELTOFA Tab. 10mg2025-06-23Drug · Prescription · Approval202501539
- MFDS drugXELTOFA Tab. 5mg2025-06-23Drug · Prescription · Approval202501540
- MFDS drugSubsidiary: (주)아이엔테라퓨틱스VELOXCAB Tab 20 mg2025-05-20Drug · Prescription · Approval202501244
- MFDS drugFexuclue 20mg film-coated tablets2025-05-12Drug · Prescription · Approval202501159
- MFDS drugBarofeno tab.2025-04-30Drug · Prescription · Approval202501049
- MFDS drugCLEANCOL Tablet2025-04-28Drug · Prescription · Approval202501006
- MFDS drugBonica-D Tab.2025-04-24Drug · OTC · Notification202500982
- MFDS drugDaewoong Ca-D Tab.2025-04-10Drug · OTC · Notification202500840
- MFDS drugImabec tablet 100mg(Imatinib mesylate)2025-03-31Drug · Prescription · Approval202500743
- MFDS drugImabec tablet 400mg(Imatinib mesylate)2025-03-31Drug · Prescription · Approval202500744
- MFDS drugDaewoongNicergolineTab.10mg2025-02-03Drug · Prescription · Approval202500213
- MFDS drugOfild tab. 150mg2025-01-16Drug · Prescription · Approval202500123
- MFDS drugOfild tab. 100mg2025-01-16Drug · Prescription · Approval202500124
- MFDS drugDaewoong Ketamine injection2025-01-08Drug · Prescription · Approval202500061
- MFDS drugdaewoong glutathione Tab. 100mg2024-12-31Drug · OTC · Notification202403110
- MFDS drugIrricol2024-12-20Drug · Prescription · Approval202403036
- MFDS drugEasy Panthenol Ointment(D-Panthenol)2024-11-28Drug · OTC · Notification202402822
- MFDS drugAmitapen Injection2024-11-26Drug · Prescription · Approval202402794
- MFDSSterile saline, wound irrigation2024-11-14Product approval · Class 2수인 24-614 호
- MFDS drugEasy End Six Ace Tab.2024-10-18Drug · OTC · Notification202402457
- MFDS drugRENCLIB tablet 75mg(Palbociclib)2024-10-07Drug · Prescription · Approval202402381
- MFDS drugRENCLIB tablet 100mg(Palbociclib)2024-10-07Drug · Prescription · Approval202402382
- MFDS drugRENCLIB tablet 125mg(Palbociclib)2024-10-07Drug · Prescription · Approval202402383
- MFDS drugC-Cold A Tab.2024-09-09Drug · OTC · Notification202402181
- MFDS drugC-Cold Night Tab.2024-09-09Drug · OTC · Notification202402182
- MFDS drugBRIDEX prefiiled syringe inj.2024-08-21Drug · Prescription · Approval202402021
- MFDS drugeasy clear cream2024-08-20Drug · OTC · Notification202402013
- MFDS drugPeramivict Premix Injection2024-08-13Drug · Prescription · Approval202401970
- MFDS drugComekina Spray2024-08-07Drug · OTC · Notification202401925
- MFDS drugMobaren 5% Foam Aerosol2024-08-01Drug · OTC · Notification202401866
- MFDS drugDUTARIMO2024-07-25Drug · Prescription · Approval202401802
- MFDS drugGinkgoShot Focus-On Capsule2024-07-25Drug · OTC · Notification202401801
- MFDS drugGluta-S Tab.2024-07-15Drug · OTC · Notification202401743
- MFDS drugMagon Shot Max Liquid2024-07-02Drug · OTC · Notification202401605
- MFDS drugMagon Shot Liquid2024-07-02Drug · OTC · Notification202401606
- MFDS drugIrricol2024-05-31Drug · Prescription · Approval202401365
- MFDS drugAPSOLA Tab.2024-04-17Drug · Prescription · Approval202400867
- MFDS drugLITORVAZET tablet 10/5mg2024-03-29Drug · Prescription · Approval202400700
- MFDS drugLet Eat Vi Pro One Tab.2024-03-26Drug · OTC · Notification202400657
- MFDS drugRabeguard Tablet 10/600mg2024-03-06Drug · Prescription · Approval202400481
- MFDS drugDaewoongNicergolineTab.30mg2024-02-29Drug · Prescription · Approval202400431
- MFDS drugJuflie Topical Solution2024-02-21Drug · Prescription · Approval202400367
- MFDS drugEasy End Six Eve Tab.2023-10-26Drug · OTC · Notification202302993
- MFDS drugEnvlomet SR Tab. 0.3/1000mg(Enavogliflozin, Metformin Hydrochloride)2023-06-13Drug · Prescription · Approval202301819
- MFDS drugRabeguard Tablet 20/600mg2023-06-08Drug · Prescription · Approval202301789
- MFDS drugMacimit2023-05-26Drug · Prescription · Approval202301686
- MFDS drugSevelmer Tab.2023-05-26Drug · Prescription · Approval202301687
- MFDS drugImpactamin Signature2023-04-18Drug · OTC · Notification202301266
- MFDS drugDaewoong Ginkgoshot Tab. 240mg2023-03-31Drug · OTC · Notification202301101
- MFDS drugCold N Tab.2023-02-23Drug · OTC · Notification202300670
- MFDS drugDW Calmadi Soft Cap.2023-02-13Drug · OTC · Notification202300522
- MFDS drugFORXILOMET XR Tab. 10/1000mg(Dapagliflozin, Metformin)2023-01-27Drug · Prescription · Approval202300356
- MFDS drugFORXILOMET XR Tab. 5/500mg(Dapagliflozin, Metformin)2023-01-18Drug · Prescription · Approval202300297
- MFDS drugFORXILOMET XR Tab. 10/500mg(Dapagliflozin, Metformin)2023-01-18Drug · Prescription · Approval202300298
- MFDS drugTafvir tab2023-01-12Drug · Prescription · Approval202300226
- MFDS drugEnvlo 0.3 mg film-coated tablets2022-11-30Drug · Prescription · Approval202204314
- MFDS drugEzn6 Night Soft capsule2022-11-22Drug · OTC · Notification202204213
- MFDS drugDexahigh Tab. 4mg2022-10-31Drug · Prescription · Approval202203949
Showing the 80 most recent of 383 records.
Clinical trials
data.go.kr213 MFDS clinical trial authorisations · 2012–2026 (Phase 1 107 · Bioequivalence 57 · Phase 3 37 · Phase 2 7 · Extension 2)
- BioequivalenceDWJ16402026-07-29
2 trial sites
- Phase 3DWP160012026-07-16
- Phase 3DWP14012정2026-07-10
7 trial sites
- Phase 1DWJ16222026-07-06
2 trial sites
- Phase 1DWJ16222026-07-06
2 trial sites
- BioequivalenceDWJ17002026-06-24
2 trial sites
- Phase 3DWP14012정2026-06-23
5 trial sites
- Phase 1DWJ14542026-04-15
2 trial sites
- Phase 1DWJ14532026-04-14
2 trial sites
- Phase 1DWJ15252026-03-18
1 trial site
- Phase 1DWJ15252026-03-18
1 trial site
- Phase 3DWP160012026-03-04
1 trial site
Show 68 more
- BioequivalenceDWJ14832026-02-12
2 trial sites
- Phase 1DWJ16212026-02-02
2 trial sites
- Phase 1DWJ16212026-02-02
2 trial sites
- BioequivalenceDWJ16722025-12-16
2 trial sites
- Phase 1DWJ16222025-11-06
2 trial sites
- Phase 1DWJ16222025-10-31
2 trial sites
- BioequivalenceDWJ16832025-10-30
1 trial site
- BioequivalenceDWJ16832025-10-30
1 trial site
- BioequivalenceDWZ25012025-09-29
16 trial sites
- BioequivalenceDWJ14452025-09-22
1 trial site
- Phase 1DWRX50032025-09-17
1 trial site
- BioequivalenceDWJ16632025-08-22
2 trial sites
- Phase 1DWP160012025-07-24
- BioequivalenceDWJ16402025-07-04
2 trial sites
- Phase 1DWJ15112025-05-28
1 trial site
- Phase 3DWP7122025-05-26
3 trial sites
- Phase 1DWRX10312025-04-28
1 trial site
- Phase 1DWJ15752025-03-04
1 trial site
- Phase 1DWJ15752025-03-04
1 trial site
- Phase 3DWJ16212024-10-11
19 trial sites
- Phase 1DWP160012024-10-09
- Phase 3DWJ16222024-09-30
20 trial sites
- Phase 1DWRX5001GOV2024-09-06
1 trial site
- BioequivalenceDWJ15892024-08-20
2 trial sites
- Phase 1DWN12088주2024-08-09
1 trial site
- Phase 3DWP160012024-06-25
8 trial sites
- Phase 1DWP2125252024-06-25
1 trial site
- BioequivalenceDWJ16072024-05-13
2 trial sites
- Phase 1DWP14012정2024-05-09
- BioequivalenceDWJ16152024-03-06
2 trial sites
- Phase 1DWP7122023-11-08
1 trial site
- Phase 1DWJ14312023-11-03
1 trial site
- Phase 1DWJ14312023-11-03
1 trial site
- Phase 3DWP160012023-10-13
3 trial sites
- Phase 3DWP14012정2023-09-26
6 trial sites
- Phase 1DWJ16222023-09-18
1 trial site
- BioequivalenceDWJ14832023-08-31
1 trial site
- BioequivalenceDWJ15682023-07-17
2 trial sites
- BioequivalenceDWJ15672023-07-17
2 trial sites
- BioequivalenceDWJ15432023-07-05
2 trial sites
- BioequivalenceDWJ15432023-07-03
2 trial sites
- Phase 1DWJ14542023-06-30
1 trial site
- Phase 1DWJ14542023-06-29
1 trial site
- BioequivalenceDWJ15732023-05-24
2 trial sites
- Phase 3DWJ16092023-05-16
7 trial sites
- Phase 1DWJ15752023-05-08
1 trial site
- Phase 1DWJ15752023-05-08
1 trial site
- BioequivalenceDWJ15412023-04-20
2 trial sites
- BioequivalenceDWJ10802023-04-03
1 trial site
- Bioequivalence대웅닌테다닙정(DWJ1531정)2023-02-28
1 trial site
- Phase 1DWP160012023-02-27
- Phase 1DWJ16101012022-12-15
1 trial site
- Phase 1DWP160012022-12-14
- Phase 1DWJ15632022-12-09
1 trial site
- Phase 3DWJ15752022-11-15
28 trial sites
- Phase 3DWP160012022-11-03
5 trial sites
- Phase 2DWN12088주2022-09-06
10 trial sites
- Phase 1DWP14012정2022-08-19
- Phase 1DWP160012022-08-10
- Phase 1DWP160012022-05-10
1 trial site
- BioequivalenceDWJ15592022-04-07
2 trial sites
- BioequivalenceDWJ15382022-03-02
2 trial sites
- Phase 1DWJ14542022-02-21
1 trial site
- Phase 1DWJ14542022-02-21
1 trial site
- Phase 1DWJ14642022-01-27
1 trial site
- BioequivalenceDWJ15402022-01-20
1 trial site
- Phase 1DWP14012정2022-01-18
- Phase 2DWP7082022-01-17
15 trial sites
Showing the 80 most recent of 213 records.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedPhase 3 · Not yet recruiting · 2027-01 · NCT07783763
Phase 3 · Not yet recruiting · 2026-10 · NCT07730138
Phase 3 · Not yet recruiting · 2026-09 · NCT07746518
Phase 3 · Not yet recruiting · 2026-06 · NCT07619833
Phase 1 · Recruiting · 2026-05 · NCT07539415
Not yet recruiting · 2026-04 · NCT07515560
Not yet recruiting · 2026-04 · NCT07558707
Phase 1 · Recruiting · 2026-04 · NCT07371104
Not yet recruiting · 2026-04 · NCT07516977
- Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer
Phase 4 · Not yet recruiting · 2026-04 · NCT07533266
Show 192 more trials
Phase 1 · Recruiting · 2025-12 · NCT07267221
Phase 1 · Completed · 2025-11 · NCT07256600
Phase 1 · Completed · 2025-11 · NCT07213310
Phase 1 · Recruiting · 2025-11 · NCT07260851
Not yet recruiting · 2025-09 · NCT07190391
Recruiting · 2025-09 · NCT07515599
Phase 1 · Recruiting · 2025-09 · NCT07144176
Phase 3 · Not yet recruiting · 2025-07 · NCT07013279
Recruiting · 2025-06 · NCT06948487
Phase 3 · Completed · 2025-02 · NCT06671392
Phase 3 · Completed · 2025-01 · NCT06682000
Phase 1 · Recruiting · 2024-12 · NCT06736587
Recruiting · 2024-12 · NCT06647888
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults
Phase 1 · Not yet recruiting · 2024-10 · NCT06644404
Phase 1 · Unknown · 2024-10 · NCT06592495
Phase 3 · Not yet recruiting · 2024-09 · NCT06606093
- to Evaluate the Safety/Tolerability and Pharmacokinetics, and Pharmacodynamics of DWP14012 Injection
Phase 1 · Unknown · 2024-07 · NCT06437951
Active not recruiting · 2024-06 · NCT06427083
Active not recruiting · 2024-06 · NCT06419816
Phase 3 · Completed · 2024-03 · NCT06062030
Phase 3 · Completed · 2024-02 · NCT06751121
Phase 3 · Unknown · 2023-12 · NCT06141980
Phase 1 · Completed · 2023-11 · NCT06212960
Phase 1 · Unknown · 2023-11 · NCT06119945
Phase 1 · Unknown · 2023-11 · NCT06109259
Phase 1 · Unknown · 2023-10 · NCT06119958
Active not recruiting · 2023-09 · NCT05926414
Phase 3 · Unknown · 2023-08 · NCT06121830
Phase 4 · Completed · 2023-08 · NCT06000657
Phase 1 · Unknown · 2023-08 · NCT06010589
Phase 1 · Unknown · 2023-08 · NCT05954338
Phase 1 · Unknown · 2023-08 · NCT05954247
Phase 3 · Unknown · 2023-08 · NCT06025409
Active not recruiting · 2023-05 · NCT05889143
Completed · 2023-05 · NCT05886933
Phase 1 · Unknown · 2023-04 · NCT05747664
Phase 3 · Unknown · 2023-03 · NCT05466643
Phase 1 · Unknown · 2023-03 · NCT05797922
Phase 1 · Unknown · 2023-02 · NCT05868967
Phase 3 · Completed · 2023-02 · NCT05643508
Phase 1 · Unknown · 2023-02 · NCT05699070
Phase 4 · Completed · 2023-02 · NCT06272630
Phase 1 · Unknown · 2023-01 · NCT05737771
- Subsidiary: (주)아이엔테라퓨틱스A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
Phase 1 · Unknown · 2022-11 · NCT06218784
Completed · 2022-11 · NCT05660122
Phase 1 · Unknown · 2022-10 · NCT05812404
Phase 1 · Withdrawn · 2022-10 · NCT05607589
Phase 3 · Unknown · 2022-09 · NCT05505994
Phase 1 · Completed · 2022-09 · NCT05574374
- Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults
Phase 1 · Unknown · 2022-08 · NCT05500898
Phase 1 · Completed · 2022-08 · NCT05816681
Phase 2 · Active not recruiting · 2022-07 · NCT05389215
Phase 1 · Completed · 2022-07 · NCT05465668
Active not recruiting · 2022-07 · NCT05614765
Completed · 2022-07 · NCT05614752
Active not recruiting · 2022-06 · NCT05411887
Active not recruiting · 2022-06 · NCT05660135
Phase 2 · Completed · 2022-05 · NCT05378360
Phase 1 · Completed · 2022-04 · NCT05192395
Phase 2 · Terminated · 2022-03 · NCT05226533
Phase 1 · Completed · 2022-03 · NCT05304845
Completed · 2022-03 · NCT06668506
Completed · 2022-02 · NCT06866509
Completed · 2022-02 · NCT05614778
Phase 1 · Unknown · 2022-02 · NCT05207176
Phase 1 · Completed · 2022-01 · NCT05832697
Phase 1 · Completed · 2022-01 · NCT06508645
Phase 3 · Completed · 2021-12 · NCT05813561
Phase 1 · Unknown · 2021-12 · NCT05321732
Phase 1 · Completed · 2021-10 · NCT05149274
Phase 4 · Completed · 2021-09 · NCT05072938
Phase 3 · Completed · 2021-09 · NCT05376930
Phase 4 · Completed · 2021-09 · NCT05410535
Phase 1 · Completed · 2021-07 · NCT04888715
Phase 1 · Completed · 2021-06 · NCT04888728
Completed · 2021-06 · NCT04926623
Phase 3 · Terminated · 2021-06 · NCT04721535
Phase 3 · Completed · 2021-05 · NCT05376969
Phase 3 · Completed · 2021-05 · NCT04784910
Phase 1 · Completed · 2021-05 · NCT05414591
Phase 1 · Completed · 2021-03 · NCT04767815
Phase 1 · Unknown · 2021-03 · NCT04819932
Phase 1 · Completed · 2021-03 · NCT04782505
Phase 3 · Terminated · 2021-02 · NCT04713176
Phase 3 · Unknown · 2021-02 · NCT04772443
Phase 1 · Unknown · 2021-01 · NCT04827472
Phase 3 · Completed · 2020-12 · NCT04654390
Phase 1 · Terminated · 2020-12 · NCT04541485
Phase 1 · Completed · 2020-11 · NCT04749173
Phase 3 · Completed · 2020-11 · NCT04634500
Unknown · 2020-11 · NCT04613895
Phase 3 · Completed · 2020-11 · NCT04632862
Phase 1 · Unknown · 2020-10 · NCT04592835
- Subsidiary: (주)아이엔테라퓨틱스A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
Phase 1 · Completed · 2020-09 · NCT05496205
Phase 2/3 · Terminated · 2020-09 · NCT04521296
Phase 1 · Completed · 2020-09 · NCT04328766
Phase 3 · Completed · 2020-08 · NCT06354127
Phase 1 · Unknown · 2020-08 · NCT04477369
Phase 1 · Unknown · 2020-08 · NCT04524052
Phase 3 · Unknown · 2020-07 · NCT04341428
Phase 1 · Unknown · 2020-06 · NCT04490434
Phase 3 · Completed · 2020-06 · NCT04341454
Phase 1 · Withdrawn · 2020-05 · NCT04393597
Phase 1 · Unknown · 2020-04 · NCT04343547
Phase 3 · Completed · 2020-03 · NCT04294251
Completed · 2020-01 · NCT05083299
Phase 1 · Unknown · 2020-01 · NCT04221399
Phase 1 · Completed · 2019-12 · NCT04159961
Phase 1 · Unknown · 2019-12 · NCT04185805
Completed · 2019-12 · NCT05184179
Phase 3 · Unknown · 2019-11 · NCT04161001
Phase 1 · Unknown · 2019-11 · NCT04167267
Phase 4 · Completed · 2019-08 · NCT04120753
Phase 1 · Completed · 2019-08 · NCT04064073
Phase 2 · Unknown · 2019-07 · NCT04014023
Phase 1 · Completed · 2019-07 · NCT04278391
Phase 1 · Unknown · 2019-06 · NCT04003441
Phase 3 · Completed · 2019-05 · NCT03946592
Phase 1 · Unknown · 2019-03 · NCT03947528
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting Conditions
Phase 1 · Completed · 2019-03 · NCT03947489
Phase 3 · Unknown · 2019-02 · NCT03811080
Phase 3 · Completed · 2018-12 · NCT03736369
Phase 1 · Completed · 2018-11 · NCT03574415
Phase 1 · Completed · 2018-05 · NCT03574285
Phase 1 · Completed · 2018-05 · NCT03573622
Phase 1 · Completed · 2018-04 · NCT03487562
Phase 4 · Completed · 2018-01 · NCT03485534
Phase 1 · Completed · 2017-12 · NCT03753477
Phase 1 · Completed · 2017-12 · NCT03364985
Phase 2 · Unknown · 2017-12 · NCT03369990
Phase 2 · Completed · 2017-10 · NCT03224117
Phase 1 · Completed · 2017-10 · NCT03512821
Phase 2 · Completed · 2017-08 · NCT03184324
Phase 3 · Terminated · 2017-07 · NCT03184415
Phase 3 · Unknown · 2017-07 · NCT03184363
Phase 1 · Completed · 2017-06 · NCT03512808
Phase 3 · Completed · 2017-04 · NCT03184402
Phase 1 · Unknown · 2017-02 · NCT03029533
Phase 1 · Unknown · 2017-01 · NCT03016520
Phase 1 · Unknown · 2017-01 · NCT03005223
Phase 3 · Completed · 2017-01 · NCT03009487
Phase 3 · Completed · 2016-12 · NCT03024086
Phase 1 · Completed · 2016-11 · NCT02952755
Phase 1 · Completed · 2016-10 · NCT02952547
Phase 2/3 · Completed · 2016-10 · NCT02947815
Phase 1 · Completed · 2016-09 · NCT02947139
Phase 3 · Unknown · 2016-08 · NCT02909270
Unknown · 2016-08 · NCT03009721
Phase 2/3 · Unknown · 2016-08 · NCT02882893
Phase 1 · Completed · 2016-03 · NCT02757144
Phase 1 · Unknown · 2016-02 · NCT03016494
Phase 1 · Unknown · 2016-01 · NCT02665832
Unknown · 2015-12 · NCT02953405
Phase 1 · Completed · 2015-12 · NCT02704559
Phase 1 · Unknown · 2015-10 · NCT02561884
Phase 3 · Completed · 2015-08 · NCT02947620
Phase 4 · Unknown · 2015-07 · NCT02648906
Phase 1 · Completed · 2015-06 · NCT02502721
Phase 3 · Completed · 2015-05 · NCT02490111
Phase 1 · Completed · 2015-05 · NCT02622685
Phase 1 · Completed · 2015-02 · NCT02385032
- Pharmacokinetics and Drug Interaction Study Between DWC20141 and DWC20142 in Healthy Male Volunteers
Phase 1 · Completed · 2015-01 · NCT02369302
Phase 4 · Completed · 2014-10 · NCT02418130
Phase 4 · Completed · 2014-10 · NCT02415777
Phase 1 · Completed · 2014-05 · NCT02089399
Phase 1 · Completed · 2014-04 · NCT02332044
Unknown · 2014-03 · NCT02946450
Phase 4 · Completed · 2014-02 · NCT02568150
Withdrawn · 2013-10 · NCT02069717
Phase 1 · Completed · 2013-09 · NCT01964365
Phase 3 · Completed · 2013-09 · NCT01945684
Phase 3 · Completed · 2012-09 · NCT01764295
Phase 1 · Unknown · 2012-09 · NCT01635686
Phase 3 · Completed · 2012-08 · NCT01636401
Phase 2 · Completed · 2012-03 · NCT01557010
Phase 3 · Completed · 2012-03 · NCT01629875
Phase 1 · Completed · 2012-02 · NCT01651858
Phase 1 · Completed · 2012-01 · NCT01653314
Phase 1 · Completed · 2012-01 · NCT01493856
Phase 1 · Terminated · 2012-01 · NCT01522586
Phase 4 · Unknown · 2011-12 · NCT01629212
Phase 1 · Completed · 2011-08 · NCT01415466
Phase 1 · Completed · 2011-08 · NCT01423526
Phase 4 · Unknown · 2011-07 · NCT01397240
Phase 4 · Completed · 2011-07 · NCT01634321
Phase 3 · Completed · 2010-10 · NCT01629199
Phase 3 · Completed · 2010-06 · NCT01634308
Phase 1 · Completed · 2010-04 · NCT01094847
Phase 1 · Completed · 2010-04 · NCT01094834
Phase 3 · Unknown · 2010-03 · NCT01099891
Phase 1 · Completed · 2009-04 · NCT00969787
Phase 3 · Completed · 2003-10 · NCT02693522
R&D and key agreements
Source: DART corporate disclosure베르시포로신(DWN12088) · 특발성 폐섬유증 · 글로벌 임상 2상 · Designated as an orphan drug and Fast Track development program by the US FDA
세마글루타이드 마이크로니들 패치 · 비만 · 임상 1상 · Core candidate in the metabolic/obesity portfolio
DWP216 · 항암 · Anticancer candidate selected for the National New Drug Development Project
DWP220 · 중증 간 섬유증 · Oral new drug candidate in development
Key disclosures
KRX KIND via OpenDARTShow 15 more events
Publications
PubMed · affiliation-matched- Enavogliflozin Improves Non-invasive Hepatic Steatosis Indices in Patients With Type 2 Diabetes: A Pooled Analysis of Three Randomised Trials.
Diabetes, obesity & metabolism · 2026-09 · Jang MK, Jung CH, Lee HS 외 8
- Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs.
Diabetes & metabolism journal · 2026-09 · Hong JH, Min KW, Lee CB 외 12
- Dual-Action Niclosamide-Polysaccharide Nasal Spray for the Early Therapeutic Intervention of Respiratory Viral Infections.
International journal of molecular sciences · 2026-06 · Choi J, Lee D, Na Y 외 7
- Real-World Data on the Efficacy and Safety of Fexuprazan in Patients with Gastroesophageal Reflux Disease: Interim Analysis of Post-Marketing Surveillance.
Gut and liver · 2026-06 · Kim JH, Lee KH, Lee WS 외 12
- Transdermal ropivacaine delivery via hydrogel-forming microneedles: A pain-free alternative for local anaesthesia.
Drug delivery and translational research · 2026-05 · Miatmoko A, Anjani QK, Octavia RT 외 7
- Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Journal of Korean medical science · 2026-05 · Chang Y, Cho YK, Kim YS 외 20
- Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000 mg in healthy subjects under fasting and fed conditions.
Naunyn-Schmiedeberg's archives of pharmacology · 2026-04 · Kim SM, Shin W, Yang AY 외 6
- Efficacy and safety of a novel sodium picosulfate oral tablet in a randomized controlled trial for bowel preparation.
World journal of gastroenterology · 2026-02 · Park SB, Kang SB, Seo GS 외 12
- The Effect of Food on the Pharmacokinetics and Gastrointestinal Tolerability of Bersiporocin, a Novel Oral Prolyl-tRNA-Synthetase Inhibitor.
Drug design, development and therapy · 2026-01 · Lee S, Kwak Y, Park J 외 3
- Authors' Reply to "Methodological and Outcome Interpretation Concerns for the Food-Effect Study of Bersiporocin" [Response to Letter].
Drug design, development and therapy · 2026-01 · Lee S, Kwak Y, Yu KS 외 1
Show 126 more publications
- A Nasal Spray Combining Camostat with a Natural Polysaccharide for the Prevention of Viral Infection via Nasal Mucosal Barrier Formation and Entry Inhibition.
International journal of molecular sciences · 2026-01 · Na Y, Kim B, Lee D 외 8
- Pharmacokinetics and Safety of Fixed-Dose Versus Separate Enavogliflozin/Gemigliptin Combinations, and Food Effect on Enavogliflozin in Healthy Korean Subjects.
Clinical and translational science · 2025-10 · Choi YS, Na J, Park SY 외 3
- Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer.
Gut and liver · 2025-09 · Hong S, Ju JH, Lee SH 외 26
- Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.
Cardiovascular diabetology · 2025-08 · Lyu YS, Lee H, Kim KS 외 2
- Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial.
BMC veterinary research · 2025-08 · An JH, Ko BG, Namkung H 외 7
- Reverse translational approach to clarify the strong potency of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor.
The Journal of pharmacology and experimental therapeutics · 2025-08 · Park SH, Ji HY, Choi JS 외 5
- Molecular perspectives on protein-modulated tear film lipid layer stability in dry eye disease.
International journal of biological macromolecules · 2025-08 · Cho G, Lee D, Song S 외 8
- SGLT2 Inhibition by Enavogliflozin Significantly Reduces Aβ Pathology and Restores Cognitive Function via Upregulation of Microglial AMPK Signaling in 5XFAD Mouse Model of Alzheimer's Disease.
Aging cell · 2025-08 · Han J, Song J, Jung ES 외 3
- Crystal structure of Fis1 and Bap31 provides information on protein-protein interactions at mitochondria-associated ER membranes.
Communications biology · 2025-08 · Nguyen MD, Kim Y, Bae SH 외 9
- Prolyl-tRNA synthetase inhibitor as a novel first-in-class keloid treatment: downregulation of de novo collagen synthesis and inflammatory cascade.
The British journal of dermatology · 2025-07 · Min S, Kim KM, Hwang J 외 5
- Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025-07 · Jeon JH, Lee J, Baek YJ 외 5
- Correction: Chun et al. Synergistic Antiviral Activity of Xanthan Gum and Camostat Against Influenza Virus Infection. Viruses 2025, 17, 301.
Viruses · 2025-04 · Chun K, Na Y, Kim B 외 5
- Synergistic Antiviral Activity of Xanthan Gum and Camostat Against Influenza Virus Infection.
Viruses · 2025-02 · Chun K, Na Y, Kim B 외 5
- Efficacy of Bone Regeneration Cell Therapy Using Mesenchymal Stem Cells Originating from Embryonic Stem Cells in Animal Models; Bone Defects and Osteomyelitis.
Tissue engineering and regenerative medicine · 2025-01 · Park JH, Bae HS, Kim I 외 6
- EPRS1-mediated fibroblast activation and mitochondrial dysfunction promote kidney fibrosis.
Experimental & molecular medicine · 2024-12 · Son SS, Jeong HS, Lee SW 외 18
- Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trial.
Diabetes, obesity & metabolism · 2024-10 · Kwak SH, Han KA, Kim ES 외 12
- Development of ropivacaine hydrochloride-loaded dissolving microneedles as a local anesthetic agent: A proof-of-concept.
International journal of pharmaceutics · 2024-07 · Ramadon D, Karn PR, Anjani QK 외 12
- The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.
Diabetes, obesity & metabolism · 2024-07 · Jeong SI, Ban MS, Hwang JG 외 9
- Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2024-06 · Seok J, Koh YG, Hong JK 외 7
- A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
Diabetes, obesity & metabolism · 2024-06 · Sohn TS, Han KA, Kim Y 외 10
- Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling.
Clinical and translational science · 2024-05 · Kim T, Jung W, Cho S 외 3
- Pharmacokinetic interactions between fexuprazan, a potassium-competitive acid blocker, and nonsteroidal anti-inflammatory drugs in healthy males.
Clinical and translational science · 2024-05 · Won H, Kim E, Chae J 외 6
- Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.
Veterinary medicine and science · 2024-05 · An JH, Choi HS, Choi JS 외 10
- Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin-converting enzyme 2.
Pharmacology research & perspectives · 2024-04 · Lee K, Na Y, Kim M 외 4
- Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials.
Cardiovascular diabetology · 2024-02 · Lyu YS, Hong S, Lee SE 외 2
- DWN12088, A Prolyl-tRNA Synthetase Inhibitor, Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis.
Diabetes & metabolism journal · 2024-01 · Lee DK, Jo SH, Lee ES 외 6
- No drug-drug interactions between selective prolyl-tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants.
Clinical and translational science · 2024-01 · Shin W, Park MY, Kim J 외 7
- Combined translational pharmacometrics approach to support the design and conduct of the first-in-human study of DWP16001.
British journal of clinical pharmacology · 2024-01 · Lee SJ, Bae SH, Jeon S 외 2
- Recombinant Human Bone Morphogenetic Protein-2 Priming of Mesenchymal Stem Cells Ameliorate Acute Lung Injury by Inducing Regulatory T Cells.
Immune network · 2023-12 · Lee J, Jang J, Cha SR 외 5
- Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms.
Immune network · 2023-12 · Lee H, Jeong OY, Park HJ 외 11
- Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.
Diabetes & metabolism journal · 2023-11 · Han KA, Kim YH, Kim DM 외 11
- Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis.
Gut and liver · 2023-11 · Kim GH, Choi MG, Kim JI 외 22
- Efficacy, Safety, and Subject Satisfaction of PrabotulinumtoxinA for Moderate-to-Severe Crow's Feet: A Phase IV, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Journal of clinical medicine · 2023-10 · Lee SK, Kim MS, Kwon SH 외 3
- A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State.
Pharmaceuticals (Basel, Switzerland) · 2023-08 · Shin W, Yang AY, Park H 외 3
- Control of fibrosis with enhanced safety via asymmetric inhibition of prolyl-tRNA synthetase 1.
EMBO molecular medicine · 2023-07 · Yoon I, Kim S, Cho M 외 18
- Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial.
Diabetes, obesity & metabolism · 2023-07 · Kwak SH, Han KA, Kim KS 외 12
- Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjects.
Clinical and translational science · 2023-07 · Park MY, Bae S, Heo JA 외 6
- Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Diabetes & metabolism · 2023-07 · Kim KS, Han KA, Kim TN 외 26
- Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
British journal of clinical pharmacology · 2023-06 · Jeong SI, Kim Y, Nah JJ 외 4
- SGLT2 inhibition ameliorates nano plastics-induced premature endothelial senescence and dysfunction.
Scientific reports · 2023-04 · Dhakal B, Shiwakoti S, Park EY 외 7
- Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects.
British journal of clinical pharmacology · 2023-04 · Kim B, Huh KY, Hwang JG 외 7
- Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans.
Pharmaceutics · 2023-03 · Kim MS, Song YK, Choi JS 외 9
- Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation.
Translational and clinical pharmacology · 2023-03 · Yang AY, Yoo H, Shin W 외 4
- Hypoxia enhances the hair growth-promoting effects of embryonic stem cell-derived mesenchymal stem cells via NADPH oxidase 4.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023-03 · Jeon SH, Kim H, Sung JH
- Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects.
Pharmaceutics · 2023-02 · Oh J, Yang E, Jang IJ 외 5
- Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects.
Expert opinion on drug metabolism & toxicology · 2023-01 · Yoon S, Park MS, Jin BH 외 4
- A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19.
Antimicrobial agents and chemotherapy · 2023-01 · Kim YS, Jeon SH, Kim J 외 31
- Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects.
British journal of clinical pharmacology · 2022-09 · Hwang JG, Lee S, Huh W 외 4
- Modulation of osteogenic differentiation by Escherichia coli-derived recombinant bone morphogenetic protein-2.
AMB Express · 2022-08 · Kim NH, Jung SK, Lee J 외 2
- Pharmacokinetics and Tissue Distribution of Enavogliflozin in Mice and Rats.
Pharmaceutics · 2022-06 · Pang M, Jeon SY, Choi MK 외 4
- Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs.
BMC veterinary research · 2022-06 · Rhee B, Mahbubur RM, Jin C 외 8
- Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
Stem cell research & therapy · 2022-04 · Karyana M, Djaharuddin I, Rif'ati L 외 11
- SLIT3 promotes myogenic differentiation as a novel therapeutic factor against muscle loss.
Journal of cachexia, sarcopenia and muscle · 2021-12 · Cho HJ, Kim H, Lee YS 외 12
- Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans.
Pharmaceutics · 2021-05 · Jeong YS, Kim MS, Lee N 외 4
- Associations of Circulating Irisin with FNDC5 Expression in Fat and Muscle in Type 1 and Type 2 Diabetic Mice.
Biomolecules · 2021-02 · Jiang S, Piao L, Ma EB 외 2
- Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.
JCI insight · 2021-01 · Lee SE, Lee SJ, Kim SE 외 4
- Evaluation of Hepatic Uptake of OATP1B Substrates by Short Term-Cultured Plated Human Hepatocytes: Comparison With Isolated Suspended Hepatocytes.
Journal of pharmaceutical sciences · 2021-01 · Yoshikado T, Lee W, Toshimoto K 외 15
- Pharmacodynamics and pharmacokinetics of DWP14012 (fexuprazan) in healthy subjects with different ethnicities.
Alimentary pharmacology & therapeutics · 2020-12 · Hwang JG, Jeon I, Park SA 외 4
- Safety and efficacy of basic fibroblast growth factors for deep second-degree burn patients.
Burns : journal of the International Society for Burn Injuries · 2020-12 · Ahn HN, Kang HS, Park SJ 외 3
- rhEGF Treatment Improves EGFR Inhibitor-Induced Skin Barrier and Immune Defects.
Cancers · 2020-10 · Kim JM, Ji JH, Kim YS 외 9
- Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs.
The AAPS journal · 2020-10 · Lee W, Koyama S, Morita K 외 13
- In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes.
Pharmaceutics · 2020-09 · Kim JH, Kim DK, Choi WG 외 5
- Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects.
Translational and clinical pharmacology · 2020-09 · Shin W, Yang AY, Yun H 외 4
- A Machine Learning-Based Identification of Genes Affecting the Pharmacokinetics of Tacrolimus Using the DMETTM Plus Platform.
International journal of molecular sciences · 2020-04 · Gim JA, Kwon Y, Lee HA 외 5
- Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
Pharmaceutics · 2020-03 · Choi MK, Nam SJ, Ji HY 외 3
- Tolerability and pharmacokinetics of ginsenosides Rb1, Rb2, Rc, Rd, and compound K after single or multiple administration of red ginseng extract in human beings.
Journal of ginseng research · 2020-03 · Choi MK, Jin S, Jeon JH 외 5
- Synergistic Adhesiveness of Fibronectin with PHSRN Peptide in Gelatin Mixture Promotes the Therapeutic Potential of Human ES-Derived MSCs.
Cellular and molecular bioengineering · 2020-02 · Kim HS, Choi SH, Kang ML 외 3
- Effects of poloxamer-based thermo-sensitive sol-gel agent on urethral stricture after transurethral resection of the prostate for benign prostatic hyperplasia: a multicentre, single-blinded, randomised controlled trial.
BJU international · 2020-01 · Chung JH, Kim KS, Choi JD 외 11
- Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.
Drug metabolism and pharmacokinetics · 2019-12 · Lee N, Maeda K, Fukizawa S 외 11
- Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2019-12 · Cheon HI, Jung N, Won CH 외 2
- Antioxidant and Cytoprotective Effects of (-)-Epigallocatechin-3-(3″-O-methyl) Gallate.
International journal of molecular sciences · 2019-08 · Kim E, Han SY, Hwang K 외 5
- A comparison study of prabotulinumtoxinA vs onabotulinumtoxinA in myostatin-deficient mice with muscle hypertrophy.
Basic & clinical pharmacology & toxicology · 2019-04 · Bak DH, Choi MJ, Lee E 외 8
- Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes for Anionic Drugs with High Binding to Human Albumin: Improvement of In Vitro-to-In Vivo Extrapolation by Considering the "Albumin-Mediated" Hepatic Uptake Mechanism on the Basis of the "Facilitated-Dissociation Model".
Drug metabolism and disposition: the biological fate of chemicals · 2019-02 · Kim SJ, Lee KR, Miyauchi S 외 1
- Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects.
Drug design, development and therapy · 2019-01 · Oh M, Shin JG, Ahn S 외 5
- A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
Clinical therapeutics · 2018-08 · Seong SJ, Kang WY, Heo JK 외 11
- Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats.
Xenobiotica; the fate of foreign compounds in biological systems · 2018-08 · Lee KR, Jeong JW, Hyun HC 외 6
- Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects.
Alimentary pharmacology & therapeutics · 2018-07 · Sunwoo J, Oh J, Moon SJ 외 6
- Effect of Red Ginseng Extract on the Pharmacokinetics and Efficacy of Metformin in Streptozotocin-Induced Diabetic Rats.
Pharmaceutics · 2018-07 · Nam SJ, Han YJ, Lee W 외 4
- Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression.
International journal of molecular sciences · 2018-04 · Kim MJ, Kang YJ, Kwon M 외 6
- Epidermal Growth Factor Attenuated the Expression of Inflammatory Cytokines in Human Epidermal Keratinocyte Exposed to Propionibacterium acnes.
Annals of dermatology · 2018-02 · Kim JM, Choo JE, Lee HJ 외 2
- Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β-Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease.
Journal of medicinal chemistry · 2018-01 · Ha HJ, Kang DW, Kim HM 외 12
- Potential protective effects of rhEGF against ultraviolet A irradiation-induced damages on human fibroblasts.
Clinical, cosmetic and investigational dermatology · 2018-01 · Kim JM, Choo JE, Kim KN 외 1
- Angiotensin II Attenuates the Bioactivities of Human Endothelial Progenitor Cells via Downregulation of β2-Adrenergic Receptor.
Stem cells international · 2018-01 · Lee SJ, Kim DY, Yun J 외 11
- Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial.
The spine journal : official journal of the North American Spine Society · 2017-12 · Cho JH, Lee JH, Yeom JS 외 11
- The Effect of Intragastric Administration of Botulinum Toxin Type A on Reducing Adiposity in a Rat Model of Obesity Using Micro-CT and Histological Examinations.
Gut and liver · 2017-11 · Park JS, Zheng HM, Kim JM 외 3
- Zebrafish as a Screening Model for Testing the Permeability of Blood-Brain Barrier to Small Molecules.
Zebrafish · 2017-08 · Kim SS, Im SH, Yang JY 외 14
- Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
Drug metabolism and disposition: the biological fate of chemicals · 2017-03 · Yim CS, Jeong YS, Lee SY 외 6
- Comparative in vitro release and clinical pharmacokinetics of leuprolide from Luphere 3M Depot, a 3-month release formulation of leuprolide acetate.
Drug development and industrial pharmacy · 2017-03 · Park S, Kim DH, Kim Y 외 4
- A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers.
Drug design, development and therapy · 2017-01 · Lee J, Kim BH, Yu KS 외 5
- Botulinum toxin injection for contouring shoulder.
Journal of the European Academy of Dermatology and Venereology : JEADV · 2017-01 · Jeong SY, Park KY, Seok J 외 3
- A Mobile Application for Wound Assessment and Treatment: Findings of a User Trial.
The international journal of lower extremity wounds · 2016-12 · Jun YJ, Shin D, Choi WJ 외 9
- Isoprene production by Escherichia coli through the exogenous mevalonate pathway with reduced formation of fermentation byproducts.
Microbial cell factories · 2016-12 · Kim JH, Wang C, Jang HJ 외 5
- Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist.
Journal of medicinal chemistry · 2016-10 · Kim SM, Lee M, Lee SY 외 9
- Resveratrol-salicylate derivatives as selective DNMT3 inhibitors and anticancer agents.
Journal of enzyme inhibition and medicinal chemistry · 2016-10 · Aldawsari FS, Aguayo-Ortiz R, Kapilashrami K 외 4
- Opuntia ficus-indica seed attenuates hepatic steatosis and promotes M2 macrophage polarization in high-fat diet-fed mice.
Nutrition research (New York, N.Y.) · 2016-04 · Kang JW, Shin JK, Koh EJ 외 3
- Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats.
Archives of pharmacal research · 2015-11 · Kim TH, Jeong JW, Song JH 외 5
- Exposure assessment of epidermal growth factor to various tissues in mice after intravenous and subcutaneous administration.
The Journal of pharmacy and pharmacology · 2015-11 · Lee JB, Shin B, Lee SH 외 4
- Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.
Journal of the neurological sciences · 2015-10 · Nam HS, Park YG, Paik NJ 외 10
- Selective retinol production by modulating the composition of retinoids from metabolically engineered E. coli.
Biotechnology and bioengineering · 2015-08 · Jang HJ, Ha BK, Zhou J 외 3
- Discovery and development of DNA methyltransferase inhibitors using in silico approaches.
Drug discovery today · 2015-05 · Medina-Franco JL, Méndez-Lucio O, Dueñas-González A 외 1
- Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
PloS one · 2015-01 · Song J, Yoo J, Kwon A 외 5
- Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects.
Clinical therapeutics · 2014-08 · Roh H, Son H, Lee D 외 3
- Acute Intravenous Injection Toxicity Study of Escherichia coli-Derived Recombinant Human Bone Morphogenetic Protein-2 in Rat.
Asian spine journal · 2014-04 · Lee JH, Lee EN, Chang BS 외 1
- Negative effect of rapidly resorbing properties of bioactive glass-ceramics as bone graft substitute in a rabbit lumbar fusion model.
Clinics in orthopedic surgery · 2014-03 · Lee JH, Ryu HS, Seo JH 외 3
- Rationalization of activity cliffs of a sulfonamide inhibitor of DNA methyltransferases with induced-fit docking.
International journal of molecular sciences · 2014-02 · Medina-Franco JL, Méndez-Lucio O, Yoo J
- Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle.
Human & experimental toxicology · 2013-09 · Kim CS, Jang WS, Son IP 외 5
- Interspecies transmission of the canine influenza H3N2 virus to domestic cats in South Korea, 2010.
The Journal of general virology · 2011-10 · Song DS, An DJ, Moon HJ 외 13
- Pathology in dogs with experimental canine H3N2 influenza virus infection.
Research in veterinary science · 2010-06 · Jung K, Lee CS, Kang BK 외 3
- Effects of epidermal growth factor on atrophic enteritis in piglets induced by experimental porcine epidemic diarrhoea virus.
Veterinary journal (London, England : 1997) · 2008-08 · Jung K, Kang BK, Kim JY 외 3
- Impact of porcine group A rotavirus co-infection on porcine epidemic diarrhea virus pathogenicity in piglets.
Research in veterinary science · 2008-06 · Jung K, Kang BK, Lee CS 외 1
- Expression of tumor necrosis factor-alpha and cyclooxygenase-2 mRNA in porcine split-thickness wounds treated with epidermal growth factor by quantitative real-time PCR.
Research in veterinary science · 2007-06 · Jung K, Park HJ, Kim YH 외 1
- Serologic surveillance of swine H1 and H3 and avian H5 and H9 influenza A virus infections in swine population in Korea.
Preventive veterinary medicine · 2007-05 · Jung K, Song DS, Kang BK 외 2
- Differential effect of phosphodiesterase IV inhibitor RP73401 on various inflammatory and immune responses relevent to rheumatoid arthritis.
Pharmacological research · 2004-05 · Cho JY, Park JS, Baik KU 외 4
- Purification of soluble human epidermal growth factor (hEGF) from recombinant Escherichia coli culture broth by using expanded-bed adsorption chromatography.
Biotechnology and applied biochemistry · 2003-08 · Lee YS, Suh CW, Park SK 외 1
- In-vitro and in-vivo immunomodulatory effects of syringin.
The Journal of pharmacy and pharmacology · 2001-09 · Cho JY, Nam KH, Kim AR 외 5
- Lignans from the rhizomes of Coptis japonica differentially act as anti-inflammatory principles.
Planta medica · 2001-06 · Cho JY, Kim AR, Park MH
- In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists.
Planta medica · 2001-04 · Cho JY, Yoo ES, Baik KU 외 2
- In vitro antiinflammatory effects of neolignan woorenosides from the rhizomes of Coptis japonica.
Journal of natural products · 2000-09 · Cho JY, Baik KU, Yoo ES 외 2
- In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa.
European journal of pharmacology · 2000-06 · Cho JY, Baik KU, Jung JH 외 1
- Inhibitor of tumor necrosis factor-alpha production in lipopolysaccharide-stimulated RAW264.7 cells from Amorpha fruticosa.
Journal of ethnopharmacology · 2000-05 · Cho JY, Kim PS, Park J 외 4
- Immunomodulatory effect of arctigenin, a lignan compound, on tumour necrosis factor-alpha and nitric oxide production, and lymphocyte proliferation.
The Journal of pharmacy and pharmacology · 1999-11 · Cho JY, Kim AR, Yoo ES 외 2
- Eudesmin inhibits tumor necrosis factor-alpha production and T cell proliferation.
Archives of pharmacal research · 1999-08 · Cho JY, Yoo ES, Baik KU 외 1
- C-terminal region of hTPO is important for secretion and expression in insect cells.
Biochemistry and molecular biology international · 1999-05 · Ahn HK, Chung JY, Park SK 외 3
- Inhibitory effect of sesquiterpene lactones from Saussurea lappa on tumor necrosis factor-alpha production in murine macrophage-like cells.
Planta medica · 1998-10 · Cho JY, Park J, Yoo ES 외 4
- Isolation and identification of inhibitory compounds on TNF-alpha production from Magnolia fargesii.
Archives of pharmacal research · 1998-02 · Chae SH, Kim PS, Cho JY 외 6
- Stabilization of human epidermal growth factor (hEGF) in aqueous formulation.
Pharmaceutical research · 1995-03 · Son K, Kwon C
Patents
KIPRIS · applicant-matchedPublished · 2026-06 · Application 1020260115696
Published · 2026-03 · Application 1020260038429
Published · 2026-02 · Application 1020260037010
Published · 2026-02 · Application 1020260036949
Registered · 2025-12 · Application 1020250200241
Published · 2025-12 · Application 1020250199389
Published · 2025-12 · Application 1020250189033
Registered · 2025-12 · Application 1020250187132
Published · 2025-11 · Application 1020250184337
Published · 2025-11 · Application 1020250184338
Show 456 more patents
Published · 2025-11 · Application 1020250184339
Published · 2025-11 · Application 1020250184340
Registered · 2025-09 · Application 1020250143150
Published · 2025-08 · Application 1020250119034
Published · 2025-08 · Application 1020250108165
Published · 2025-06 · Application 1020250085703
Published · 2025-06 · Application 1020250085701
Published · 2025-06 · Application 1020250085702
Published · 2025-06 · Application 1020250082845
Registered · 2025-04 · Application 1020250057769
Published · 2025-02 · Application 1020250015932
CN · Published · 2025-01 · Application 202510122452.5
CN · Published · 2025-01 · Application 202510122944.4
TW · Published · 2025-01 · Application 114103481
TW · Registered · 2025-01 · Application 114103480
Published · 2025-01 · Application 1020267024430
Published · 2025-01 · Application 1020267025163
PCT · Published · 2025-01 · Application PCT/KR2025/001408
PCT · Published · 2025-01 · Application PCT/KR2025/001405
TW · Published · 2025-01 · Application 114102257
CN · Published · 2025-01 · Application 202510009142.2
TW · Published · 2025-01 · Application 114100252
Published · 2025-01 · Application 1020267024623
PCT · Published · 2025-01 · Application PCT/KR2025/000078
Published · 2024-12 · Application 1020240197825
Published · 2024-12 · Application 1020240197827
Published · 2024-12 · Application 1020240198659
Published · 2024-12 · Application 1020240194238
- Subsidiary: (주)아이엔테라퓨틱스5-클로로-2-플루오로-4-((4-플루오로-2-(메틸(2-(메틸아미노)에틸)아미노)페닐)아미노)-N-(티아졸-4-일)벤젠설폰아마이드의신규 염 및 이의 제조방법
Published · 2024-12 · Application 1020240188619
TW · Published · 2024-12 · Application 113147251
TW · Registered · 2024-12 · Application 113147144
TW · Registered · 2024-12 · Application 113147146
CN · Published · 2024-11 · Application 202411684750.5
TW · Registered · 2024-11 · Application 113145038
Published · 2024-11 · Application 1020267016421
PCT · Published · 2024-11 · Application PCT/KR2024/018578
Published · 2024-11 · Application 1020240164582
Published · 2024-11 · Application 1020240164590
- Subsidiary: (주)아피셀테라퓨틱스표적에 특이적으로 결합하는 스테핀 A 단백질 변이체를 포함하는 세포외 소포 및 이의 용도
Published · 2024-10 · Application 1020240147534
- Subsidiary: (주)아피셀테라퓨틱스TNFR2 결합 에이전트를 인코딩하는 핵산을 포함하는 유전자 변형된 세포 및 이의 용도
Published · 2024-09 · Application 1020240130803
TW · Published · 2024-09 · Application 113136260
Published · 2024-09 · Application 1020240129594
TW · Published · 2024-08 · Application 113129892
Registered · 2024-08 · Application 1020240106531
CN · Published · 2024-07 · Application 202410937551.4
TW · Published · 2024-07 · Application 113126116
Published · 2024-07 · Application 1020267003466
PCT · Published · 2024-07 · Application PCT/KR2024/009997
EP · Published · 2024-05 · Application 24823608.5
Published · 2024-05 · Application 1020240062866
Published · 2024-05 · Application 1020240061553
CN · Published · 2024-05 · Application 202480026639.9
TW · Published · 2024-05 · Application 113116470
TW · Registered · 2024-05 · Application 114138107
Registered · 2024-05 · Application 1020240058943
CN · Published · 2024-04 · Application 202410515494.0
TW · Published · 2024-04 · Application 113115667
PCT · Published · 2024-04 · Application PCT/KR2024/005661
Published · 2024-04 · Application 1020240046979
Published · 2024-03 · Application 1020240040267
- Subsidiary: (주)대웅이엔지나잘 스프레이 케이스
Registered · 2024-03 · Application 1020240034885
Registered · 2024-02 · Application 1020240017190
Published · 2024-01 · Application 1020240006933
- Subsidiary: (주)아피셀테라퓨틱스CD40L 결합 제제를 암호화하는 핵산을 포함하는 유전자 변형된 세포 및 이의 용도
Published · 2023-12 · Application 1020257024641
CN · Published · 2023-12 · Application 202380089531.X
US · Published · 2023-12 · Application 19143621
EP · Published · 2023-12 · Application 23912987.7
Registered · 2023-12 · Application 1020230192195
- Subsidiary: (주)대웅이엔지나잘 스프레이
Rejected · 2023-11 · Application 1020230157410
- Subsidiary: (주)대웅이엔지나잘 스프레이
Rejected · 2023-11 · Application 1020230157409
US · Published · 2023-11 · Application 19121924
EP · Published · 2023-11 · Application 23889193.1
- Subsidiary: (주)대웅이엔지분말 혼합용기
Rejected · 2023-11 · Application 1020230153915
- Subsidiary: (주)대웅이엔지나잘 스프레이
Rejected · 2023-11 · Application 1020230151727
- Subsidiary: (주)대웅이엔지분말 혼합용기
Registered · 2023-10 · Application 1020230148229
CN · Published · 2023-10 · Application 202380071222.X
Registered · 2023-10 · Application 1020230135713
TW · Published · 2023-10 · Application 112138910
EP · Published · 2023-10 · Application 23877700.7
CN · Published · 2023-10 · Application 202380071096.8
Rejected · 2023-10 · Application 1020230132855
US · Published · 2023-10 · Application 19118085
EP · Published · 2023-10 · Application 23875239.8
- Subsidiary: (주)아피셀테라퓨틱스TNFR2 결합 폴리펩타이드 및 이의 용도의 방법
Published · 2023-09 · Application 1020257033413
CN · Published · 2023-09 · Application 202380069758.8
US · Published · 2023-09 · Application 19115424
EP · Published · 2023-09 · Application 23873190.5
Published · 2023-09 · Application 1020230130349
CN · Published · 2023-09 · Application 202380064560.0
Registered · 2023-09 · Application 1020230119824
US · Published · 2023-09 · Application 19109652
EP · Published · 2023-09 · Application 23863561.9
Published · 2023-09 · Application 1020230117859
- Subsidiary: (주)아이엔테라퓨틱스ELECTROPHYSIOLOGICAL EVALUATION METHOD FOR DRUG EFFICACY BY USING IN-VIVO EXTRACELLULAR DORSAL ROOT GANGLION RECORDING METHOD
PCT · Published · 2023-08 · Application PCT/KR2023/012835
Published · 2023-06 · Application 1020230085139
Registered · 2023-06 · Application 1020230075141
CN · Published · 2023-06 · Application 202380040476.5
Registered · 2023-06 · Application 1020230073267
PCT · Published · 2023-04 · Application PCT/US2023/019630
Registered · 2023-04 · Application 1020230050502
- Subsidiary: (주)대웅이엔지가공배전선간의 안전한 연결을 위한 가공배전기기
Registered · 2023-03 · Application 1020230039631
- Subsidiary: (주)대웅이엔지변압기로의 가공배전선 분기가 가능한 가공배전선 지지설비
Registered · 2023-03 · Application 1020230039642
- Subsidiary: (주)대웅이엔지분기기능을 갖춘 다기능 가공배전선 지지장치
Registered · 2023-03 · Application 1020230039638
- Subsidiary: (주)대웅이엔지고정성이 향상된 가공배전선 지지장치
Registered · 2023-03 · Application 1020230039748
- Subsidiary: (주)아이엔테라퓨틱스ELECTROPHYSIOLOGICAL EVALUATION METHOD FOR DRUG EFFICACY BASED ON IN VIVO PATCH-CLAMP TECHNIQUE
PCT · Published · 2023-03 · Application PCT/KR2023/003826
Registered · 2023-02 · Application 1020230020155
- Subsidiary: (주)아피셀테라퓨틱스CD40L에 특이적으로 결합하는 스테핀 A 단백질 변이체 및 이의 용도
Registered · 2023-02 · Application 1020230018017
Registered · 2023-02 · Application 1020230014993
CN · Published · 2023-01 · Application 202380017361.4
EP · Published · 2023-01 · Application 23743525.0
Published · 2023-01 · Application 1020230005118
CN · Published · 2022-12 · Application 202280083031.0
Published · 2022-12 · Application 1020220190502
US · Published · 2022-12 · Application 18722507
EP · Published · 2022-12 · Application 22916827.3
US · Published · 2022-12 · Application 18718904
EP · Published · 2022-12 · Application 22908005.6
Registered · 2022-12 · Application 1020220176833
Published · 2022-12 · Application 1020220175620
Registered · 2022-12 · Application 1020220174223
Published · 2022-11 · Application 1020220150695
Registered · 2022-11 · Application 1020220146295
CN · Published · 2022-09 · Application 202280066565.2
US · Published · 2022-09 · Application 18696065
EP · Published · 2022-09 · Application 22876888.3
Registered · 2022-09 · Application 1020220123680
Registered · 2022-09 · Application 1020220123673
- Subsidiary: (주)아이엔테라퓨틱스인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법
Registered · 2022-08 · Application 1020220109836
Registered · 2022-08 · Application 1020220100230
Registered · 2022-08 · Application 1020220100231
US · Registered · 2022-07 · Application 17874700
CN · Published · 2022-07 · Application 202280051585.2
TW · Published · 2022-07 · Application 111127532
Registered · 2022-07 · Application 1020220090701
EP · Published · 2022-07 · Application 22846286.7
CN · Published · 2022-05 · Application 202280036629.4
Published · 2022-05 · Application 1020220064451
Published · 2022-05 · Application 1020220064452
EP · Published · 2022-05 · Application 22811663.8
TW · Published · 2022-05 · Application 112142889
TW · Published · 2022-05 · Application 111119457
CN · Published · 2022-05 · Application 202280036648.7
US · Published · 2022-05 · Application 18562428
EP · Published · 2022-05 · Application 22805024.1
Rejected · 2022-05 · Application 1020220061797
TW · Published · 2022-05 · Application 111118047
TW · Published · 2022-05 · Application 111118048
Rejected · 2022-05 · Application 1020220055598
CN · Published · 2022-05 · Application 202280033307.4
CN · Published · 2022-05 · Application 202280034620.X
Published · 2022-05 · Application 1020220054168
Registered · 2022-05 · Application 1020220054169
US · Published · 2022-05 · Application 18288275
US · Registered · 2022-05 · Application 18288296
EP · Published · 2022-05 · Application 22807683.2
EP · Published · 2022-05 · Application 22807684.0
Registered · 2022-04 · Application 1020220047811
- Subsidiary: (주)아이엔테라퓨틱스인비보 패치 클램프 기법을 이용한 전기생리학적 약효 평가법
Registered · 2022-03 · Application 1020220036909
- Subsidiary: (주)대웅이엔지인공지능을 통한 과립공정 최적화 시스템 및 방법
Registered · 2022-02 · Application 1020220017138
Published · 2022-01 · Application 1020220008671
Registered · 2022-01 · Application 1020220005965
Published · 2021-12 · Application 1020210192406
Registered · 2021-12 · Application 1020210182187
TW · Registered · 2021-12 · Application 110147512
EP · Registered · 2021-12 · Application 21907148.7
Registered · 2021-12 · Application 1020210181342
Rejected · 2021-12 · Application 1020210174960
Published · 2021-09 · Application 1020210130239
CN · Published · 2021-08 · Application 202180052254.6
TW · Published · 2021-08 · Application 110131531
TW · Published · 2021-08 · Application 110131530
EP · Published · 2021-08 · Application 21862057.3
Registered · 2021-08 · Application 1020210112204
Registered · 2021-07 · Application 1020210086988
Registered · 2021-05 · Application 1020210066213
- Subsidiary: (주)대웅이엔지약품 검사장치
Registered · 2021-05 · Application 1020210062985
Registered · 2021-03 · Application 1020210036824
Registered · 2021-02 · Application 1020210026669
Registered · 2021-02 · Application 1020210025655
Withdrawn · 2021-01 · Application 1020210011074
Registered · 2021-01 · Application 1020210008288
US · Registered · 2021-01 · Application 17151901
Published · 2020-12 · Application 1020200181551
Registered · 2020-12 · Application 1020200178050
CN · Published · 2020-12 · Application 202411878355.0
CN · Published · 2020-12 · Application 202080087191.3
EP · Registered · 2020-12 · Application 20902925.5
Registered · 2020-12 · Application 1020200171580
EP · Registered · 2020-11 · Application 20892809.3
Registered · 2020-11 · Application 1020200159502
Registered · 2020-10 · Application 1020200143415
Rejected · 2020-10 · Application 1020200136628
Registered · 2020-09 · Application 1020237008078
Rejected · 2020-08 · Application 1020200107083
Registered · 2020-08 · Application 1020200106002
US · Published · 2020-08 · Application 17637178
EP · Published · 2020-08 · Application 20857855.9
Registered · 2020-08 · Application 1020200101136
Registered · 2020-07 · Application 1020200084549
Rejected · 2020-06 · Application 1020200077338
Registered · 2020-02 · Application 1020200024593
US · Published · 2020-02 · Application 17434389
EP · Published · 2020-02 · Application 20763321.5
EP · Published · 2020-02 · Application 20762973.4
Registered · 2020-02 · Application 1020200024592
Registered · 2020-02 · Application 1020200023817
CN · Published · 2020-02 · Application 202080017133.3
US · Registered · 2020-02 · Application 17431464
EP · Registered · 2020-02 · Application 20763090.6
Abandoned · 2019-12 · Application 1020190178018
US · Registered · 2019-12 · Application 16718300
Registered · 2019-11 · Application 1020190156418
EP · Registered · 2019-09 · Application 19863941.1
Registered · 2019-09 · Application 1020190110997
CN · Published · 2019-08 · Application 201980056437.8
US · Registered · 2019-08 · Application 17269325
Registered · 2019-08 · Application 1020190104641
Registered · 2019-08 · Application 1020190097311
Registered · 2019-07 · Application 1020190091235
Registered · 2019-05 · Application 1020190056741
US · Registered · 2019-05 · Application 16411270
Registered · 2019-04 · Application 1020190048759
Expired · 2019-04 · Application 1020190040780
Rejected · 2018-12 · Application 1020180172103
US · Registered · 2018-12 · Application 16770213
EP · Registered · 2018-12 · Application 18896304.5
EP · Registered · 2018-12 · Application 18897615.3
EP · Registered · 2018-12 · Application 18894845.9
Registered · 2018-12 · Application 1020180171938
Registered · 2018-11 · Application 1020217015299
Registered · 2018-11 · Application 1020217015300
Expired · 2018-10 · Application 1020180122241
EP · Registered · 2018-10 · Application 18865651.6
Registered · 2018-08 · Application 1020180092244
Registered · 2018-08 · Application 1020180092243
CN · Published · 2018-07 · Application 201880044152.8
EP · Registered · 2018-07 · Application 18832644.1
CN · Published · 2018-07 · Application 201880046671.8
EP · Registered · 2018-07 · Application 18832639.1
Registered · 2018-07 · Application 1020180079611
Rejected · 2018-06 · Application 1020180075290
US · Published · 2018-05 · Application 16618219
Registered · 2018-05 · Application 1020180050669
Registered · 2018-05 · Application 1020180050671
Registered · 2018-05 · Application 1020180050670
US · Published · 2018-04 · Application 16604173
EP · Registered · 2018-04 · Application 18784969.0
Registered · 2018-04 · Application 1020197029219
Registered · 2018-04 · Application 1020197029212
Registered · 2018-02 · Application 1020180023953
Registered · 2018-02 · Application 1020180023954
Registered · 2018-02 · Application 1020180023952
- Subsidiary: (주)대웅이엔지클램프를 활용한 가공배전선 고정장치
Registered · 2018-02 · Application 1020180017546
- Subsidiary: (주)대웅이엔지보수가 용이한 가공배전선 고정장치
Registered · 2018-02 · Application 1020180016907
TW · Published · 2018-02 · Application 110116961
PCT · Published · 2018-02 · Application PCT/KR2018/001625
Registered · 2018-02 · Application 1020180015091
Registered · 2018-01 · Application 1020180007928
Expired · 2018-01 · Application 1020180005052
Expired · 2018-01 · Application 1020180005051
Registered · 2017-12 · Application 1020170183060
Registered · 2017-12 · Application 1020170183062
Registered · 2017-11 · Application 1020170152276
PCT · Published · 2017-11 · Application PCT/KR2017/012559
PCT · Published · 2017-10 · Application PCT/KR2017/011964
PCT · Published · 2017-10 · Application PCT/KR2017/011963
Registered · 2017-10 · Application 1020170131349
Registered · 2017-07 · Application 1020170086528
PCT · Published · 2017-07 · Application PCT/KR2017/007281
Expired · 2017-06 · Application 1020170083495
Registered · 2017-06 · Application 1020170083259
Registered · 2017-06 · Application 1020170078745
Registered · 2017-06 · Application 1020170075799
EP · Registered · 2017-06 · Application 17810558.1
Registered · 2017-05 · Application 1020170067646
Registered · 2017-05 · Application 1020170067639
Withdrawn · 2017-05 · Application 1020170067672
Expired · 2017-03 · Application 1020170039962
Withdrawn · 2017-03 · Application 1020170036602
US · Registered · 2017-03 · Application 16073359
Registered · 2017-03 · Application 1020170034059
Registered · 2017-03 · Application 1020170033749
Rejected · 2017-02 · Application 1020170018336
Registered · 2017-01 · Application 1020170011746
- Subsidiary: (주)힐리언스HEALTHCARE SUPPORT SYSTEM FOR MOBILE ONLY AND METHOD FOR IMPLEMENTING SAME
PCT · Published · 2017-01 · Application PCT/KR2017/000604
Registered · 2016-11 · Application 1020160150511
Registered · 2016-11 · Application 1020160148262
PCT · Published · 2016-09 · Application PCT/KR2016/010502
US · Registered · 2016-06 · Application 15556352
PCT · Published · 2016-06 · Application PCT/KR2016/005999
US · Registered · 2016-04 · Application 15520518
PCT · Published · 2016-04 · Application PCT/KR2016/004411
Registered · 2016-04 · Application 1020160043522
Registered · 2016-03 · Application 1020160036080
Registered · 2016-03 · Application 1020160033813
Expired · 2016-03 · Application 1020160029083
- Subsidiary: (주)아이엔테라퓨틱스SODIUM CHANNEL BLOCKERS
EP · Registered · 2016-02 · Application 16749473.1
Registered · 2016-02 · Application 1020160013588
PCT · Published · 2016-01 · Application PCT/KR2016/000935
TW · Published · 2016-01 · Application 105102582
US · Registered · 2016-01 · Application 15542550
PCT · Published · 2016-01 · Application PCT/KR2016/000398
Withdrawn · 2015-12 · Application 1020150190850
Registered · 2015-10 · Application 1020150147513
Withdrawn · 2015-07 · Application 1020150108799
Rejected · 2015-07 · Application 1020150108302
US · Registered · 2015-06 · Application 15312192
Registered · 2015-06 · Application 1020150088872
Registered · 2015-06 · Application 1020150080722
US · Published · 2015-05 · Application 15314282
PCT · Published · 2015-05 · Application PCT/KR2015/004826
Registered · 2015-05 · Application 1020150067176
Expired · 2015-04 · Application 1020150057785
Expired · 2015-04 · Application 1020150057784
Rejected · 2015-04 · Application 1020150056977
Registered · 2015-04 · Application 1020150053068
Rejected · 2015-03 · Application 1020150035141
Registered · 2015-03 · Application 1020150034679
Expired · 2015-02 · Application 1020150025899
Expired · 2015-02 · Application 1020150025898
Expired · 2015-02 · Application 1020150025897
- Subsidiary: (주)아이엔테라퓨틱스소디움 채널 차단제
Registered · 2015-02 · Application 1020150021160
Registered · 2015-01 · Application 1020150006561
Withdrawn · 2014-10 · Application 1020140144384
PCT · Published · 2014-10 · Application PCT/KR2014/009876
PCT · Published · 2014-10 · Application PCT/KR2014/009353
Registered · 2014-09 · Application 1020140123533
Registered · 2014-09 · Application 1020140117452
Registered · 2014-09 · Application 1020140117455
PCT · Published · 2014-09 · Application PCT/KR2014/008287
Registered · 2014-09 · Application 1020140117450
US · Registered · 2014-08 · Application 14913696
Expired · 2014-08 · Application 1020140109333
Expired · 2014-08 · Application 1020140108079
Expired · 2014-08 · Application 1020140105809
Registered · 2014-06 · Application 1020140074778
Registered · 2014-06 · Application 1020140066913
Registered · 2014-02 · Application 1020140018452
Registered · 2014-01 · Application 1020140007556
Registered · 2013-12 · Application 1020130162424
Registered · 2013-12 · Application 1020130157198
Expired · 2013-12 · Application 1020130150076
Registered · 2013-11 · Application 1020130133807
Expired · 2013-10 · Application 1020130128154
US · Registered · 2013-10 · Application 14435473
EP · Registered · 2013-10 · Application 18198388.3
Registered · 2013-10 · Application 1020130122783
Registered · 2013-10 · Application 1020130118189
Withdrawn · 2013-09 · Application 1020130106098
Registered · 2013-08 · Application 1020130103471
Registered · 2013-06 · Application 1020130069251
CN · Published · 2013-03 · Application 201380018083
US · Published · 2013-03 · Application 14388115
Registered · 2013-03 · Application 1020130030734
US · Registered · 2013-01 · Application 14370327
Registered · 2013-01 · Application 1020130000842
Expired · 2012-12 · Application 1020120156100
CN · Published · 2012-11 · Application 201280058933
CN · Published · 2012-11 · Application 201280058939
Expired · 2012-11 · Application 1020120136186
US · Registered · 2012-11 · Application 14361365
Expired · 2012-11 · Application 1020120136199
Expired · 2012-10 · Application 2020120009700
Withdrawn · 2012-06 · Application 1020120070455
Expired · 2012-04 · Application 1020120045767
Registered · 2012-04 · Application 1020120035107
Registered · 2012-02 · Application 1020120015465
CN · Published · 2011-10 · Application 201180048900
PCT · Published · 2011-10 · Application PCT/KR2011/007635
TW · Published · 2011-10 · Application 100136386
Registered · 2011-09 · Application 1020110098257
Withdrawn · 2011-09 · Application 1020110091558
- Subsidiary: (주)대웅이엔지절연기능을 향상시킨 특고압 전용라인 배전용 커넥터
Registered · 2011-05 · Application 1020110048420
Expired · 2011-05 · Application 2020110004058
Registered · 2011-04 · Application 1020110036844
Expired · 2011-04 · Application 1020110036854
Expired · 2011-03 · Application 1020110029931
Registered · 2011-02 · Application 1020110012523
Registered · 2010-10 · Application 1020100099910
CN · Published · 2010-09 · Application 201080040212
PCT · Published · 2010-09 · Application PCT/KR2010/006193
PCT · Published · 2010-09 · Application PCT/KR2010/006192
Registered · 2010-07 · Application 1020100073520
Registered · 2010-04 · Application 1020100033295
Rejected · 2010-03 · Application 1020100027523
PCT · Published · 2010-03 · Application PCT/KR2010/001867
Rejected · 2010-03 · Application 1020100025487
Expired · 2010-03 · Application 1020100022839
Expired · 2010-03 · Application 1020100022529
Registered · 2010-03 · Application 1020100022276
PCT · Published · 2009-10 · Application PCT/KR2009/005827
Expired · 2009-10 · Application 2020090013055
Registered · 2009-09 · Application 1020090086149
Registered · 2009-09 · Application 1020090086151
Registered · 2009-09 · Application 1020090086150
Expired · 2009-09 · Application 1020090085014
Rejected · 2009-09 · Application 1020090084641
Expired · 2009-08 · Application 2020090010417
Expired · 2009-08 · Application 2020090010418
TW · Published · 2009-04 · Application 098112800
Registered · 2009-04 · Application 1020090033268
JP · Registered · 2009-04 · Application 23504927
Expired · 2008-12 · Application 1020080121319
Registered · 2008-11 · Application 1020080112366
Expired · 2008-11 · Application 1020080111741
Rejected · 2008-10 · Application 2020080014267
Registered · 2008-07 · Application 1020080073250
Rejected · 2008-07 · Application 1020080068217
Rejected · 2008-07 · Application 2020080009294
Expired · 2008-05 · Application 2020080007037
Expired · 2008-04 · Application 1020080031856
Registered · 2007-12 · Application 1020097012702
Expired · 2007-10 · Application 1020070108007
Expired · 2007-08 · Application 1020070083703
Registered · 2007-07 · Application 1020097002033
PCT · Published · 2007-07 · Application PCT/KR2007/003362
JP · Registered · 2007-05 · Application 21509439
Expired · 2007-04 · Application 1020070037108
Expired · 2007-04 · Application 1020070033033
Registered · 2007-03 · Application 1020070022948
PCT · Published · 2007-01 · Application PCT/KR2007/000436
Withdrawn · 2006-12 · Application 1020060139039
Registered · 2006-10 · Application 1020087012856
Expired · 2006-08 · Application 1020060076619
Registered · 2006-06 · Application 1020060053441
Registered · 2006-05 · Application 1020060042462
Expired · 2006-04 · Application 1020060038105
Expired · 2006-04 · Application 1020060032187
Expired · 2006-03 · Application 1020077025204
Expired · 2006-03 · Application 1020060025014
Expired · 2006-01 · Application 1020077018961
PCT · Published · 2006-01 · Application PCT/KR2006/000324
Expired · 2006-01 · Application 1020060008379
Expired · 2006-01 · Application 1020060001303
Expired · 2005-12 · Application 1020050134837
Expired · 2005-12 · Application 1020050122460
Expired · 2005-12 · Application 1020050121605
Withdrawn · 2005-10 · Application 1020050098349
Rejected · 2005-08 · Application 1020050080825
Expired · 2005-08 · Application 1020050080180
Expired · 2005-08 · Application 2020050024804
Expired · 2005-07 · Application 1020050062702
Expired · 2005-05 · Application 1020050038841
Expired · 2005-05 · Application 1020050038441
Withdrawn · 2004-12 · Application 1020040106635
Expired · 2004-07 · Application 1020040057864
PCT · Published · 2004-07 · Application PCT/KR2004/001764
Rejected · 2004-07 · Application 1020040052758
Expired · 2004-07 · Application 1020040052714
Expired · 2004-07 · Application 1020040052713
PCT · Published · 2001-04 · Application PCT/KR2001/000579
PCT · Published · 2001-04 · Application PCT/KR2001/000578
PCT · Published · 1999-06 · Application PCT/KR1999/000327
PCT · Published · 1999-04 · Application PCT/KR1999/000209
PCT · Published · 1999-03 · Application PCT/KR1999/000095
PCT · Published · 1998-03 · Application PCT/KR1998/000048
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot40
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 25, 2026 · 5 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for DAEWOONG PHARMA and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
CLASSYS Inc., established in 2015 and listed on KOSDAQ, makes aesthetic medical devices using HIFU, MRF, MNRF, and laser technologies.
Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.
Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.
Founded and KOSDAQ-listed in 2018, WSI distributes spine/joint devices and has expanded into medical robots and pharma via subsidiaries.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition